Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

Allaysis is a pharmaceutical firm focused on identifying and developing medication formulations for tiny patient populations. Its purpose is to meet the growing need for pharmacological products tailored exclusively for the treatment of patients with uncommon illnesses or disabilities. Because of a lack of funding for vital research work, many of these patients are unable to benefit from much-needed medicinal products. They develop dosage forms, sponsor clinical trials, and guide the chemical through regulatory approval to make these treatments available to underserved patients by creating relationships with drug development and research teams in both academia and industry.

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Richter Gedeon Nyrt deals with pharmaceutical production, research and development, trade, and marketing.

TerSera Therapeutics LLC develops pharmaceutical products. Its therapeutic areas include allergy or immunology, CNS disorders, endocrinology, gastroenterology, infectious disease, oncology, orphan diseases, rheumatology, transplant-related therapies, urology, and women's health. The company was founded by Edward J. Fiorentino in 2016 and is headquartered in Lake Forest, IL.

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Etypharm is a French private company, also operating in FR. The firm provides healthcare services.

Clinical Research Associates is a medical research center that focused on providing clinical data.

Servier Laboratories (doing business as Les Laboratories Servier) is a French private company located in Paris. The firm operates as a pharmaceutical company.\nThe company says this about itself: Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities. A leader in cardiology, the ambition of the Servier Group is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Azurity Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on the needs of patients, especially children and the elderly, requiring customized, user-friendly drug formulations. The firm?s products include Epaned, Qbrelis, Xatmep and FIRVANQ oral solutions. The company was founded in 1998 and is headquartered in Woburn, MA.

Slayback is founded on the principle of “connecting the dots”. This principle translates into their philosophy of connecting one idea with another. The idea is to conceptualize and develop complex generic and specialty drugs. They focus on products that are challenging and highly complex to develop and/or manufacture. It could be a complex oil-in-water emulsion or a sterile long acting injectable using nano-spheres or sterile suspensions with complex particle physics. They have also worked on complex hormonal products with challenging cross-contamination issues. They aim to optimize the use of technology and potential (generated from a strong experience in this field) to develop a value proposition for their customers. Through this process of drug development, they remotely aim at reducing the cost of therapy by bringing expensive branded drugs within the reach of patients.

AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland.

Seaside Therapeutics was founded to translate promising research discoveries into effective treatments for patients with autism, fragile X syndrome and other disorders of brain development. Our vision is to successfully develop breakthrough medications that will meaningfully improve the lives of individuals with these disorders.

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Part of Jazz Pharmaceuticals Plc, Jazz Pharmaceuticals International Ltd. is a company headquartered in Hamilton, Bermuda, that operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products.

Medrx Co. Ltd. engages in the business of pharmaceutical drug development based on the transdermal absorption. It develops new value-added medicines by the drug formulation technology based on ILTS (Ionic Liquid Transdermal System), a unique technologies using ionic liquid and unique transdermal drug delivery technology using nano-sized colloid transdermal system for drugs. The company was founded by Masayoshi Matsumura on January 15, 2002 and is headquartered in Higashikagawa, Japan.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.